Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Pharma PLC declared that its Board of Directors has initiated a stock buyback plan on Sunday, June 4th 2017, which allows the company to repurchase 1,000% of outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board believes its shares are undervalued.

Horizon Pharma PLC (NASDAQ:HZNP) posted its earnings results on Monday, August, 7th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.12 by $0.29. The business earned $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. Horizon Pharma PLC's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 EPS. View Horizon Pharma PLC's Earnings History.

Horizon Pharma PLC is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Horizon Pharma PLC.

11 equities research analysts have issued twelve-month target prices for Horizon Pharma PLC's stock. Their forecasts range from $12.00 to $30.00. On average, they anticipate Horizon Pharma PLC's stock price to reach $18.91 in the next year. View Analyst Ratings for Horizon Pharma PLC.

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

• 1. Cantor Fitzgerald analysts commented, "We are maintaining our Overweight rating and $17, 12 month PT for HZNP shares, but lowering our 2017 and 2018 EPS estimates because we have taken out some sales for the Raptor franchise now that Horizon has completed the sale of its EU marketing rights to Chiesi (Not Covered). We continue to expect Krystexxa sales to be impacted by the 340b program in 4Q17, which could prove conservative. Please see our note for details Potential HHS Delay Could Be Positive for HZNP’s Krystexxa Sales This Year. We expect orphan drug sales to increase 50% YOY which is in line with Horizon’s guidance, and rheumatology sales to increase 37% YOY, which is also roughly in line with Horizon’s guidance. Valuation. We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $17." (9/11/2017)
• 2. According to Zacks Investment Research, "Horizon’s second-quarter results were impressive with the company beating on both the top and bottom line estimates. Moreover, the increase in sales guidance for 2017 was encouraging as well. However, revenues from primary care business units declined due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. Moreover, in Jun 2017, Horizon Pharma sold the marketing rights for Procysbi and Quinsair in the Europe, the Middle East and Africa regions to Chiesi Farmaceutici S.p.A. as the company focuses on higher-return businesses. Shares of the company have underperformed the industry. With the company’s efforts to expand Actimmune’s label suffered a setback, focus will be on Krystexxa’s performance. Stiff competition for drugs will also impact sales." (8/11/2017)
• 3. Piper Jaffray Companies analysts commented, "We had the opportunity to travel with Horizon senior management in meetings with investors. We gained additional insight into Pennsaid 2% and Ravicti, and also came away with insights into management's latest thinking regarding M&A. Though there are undoubtedly some headwinds facing the primary care segment, we believe that this segment should be on largely stable footing over the long-term given HZNP's payer contracting efforts. That dynamic combined with continued strength from the rare disease segment points to a long-term EPS CAGR (2017-2022) in the mid-teens, and should translate into multiple expansion with a 2017E P/E currently at 7x. We reiterate our Overweight rating and are lowering our PT to $30 from $32 (see below for more details)." (3/24/2017)
• 4. Guggenheim analysts commented, "HZNP reported a 4Q16 beat, underscoring our confidence that HZNP can continue to meet or exceed earnings expectations in '17+. Post 4Q16, we think that the peak sales potential of Pennsaid 2%, Procysbi, and Krystexxa are underappreciated, with additional earnings upside potentially coming from M&A as HZNP redeploys cash generated by its Primary Care ("PC") business into business development focused on orphan and rare disease indication medicines. While concerns remain over growth prospects for HZNP's PC business, Ravicti and Actimmune, these assets continue to generate meaningful cash to fuel HZNP's growth aspiration of $2B in sales by 2020." (2/27/2017)
• 5. Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)

Horizon Pharma PLC saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 19,875,636 shares, a decrease of 6.6% from the August 15th total of 21,291,050 shares. Based on an average daily trading volume, of 3,273,655 shares, the days-to-cover ratio is presently 6.1 days. Currently, 12.3% of the shares of the company are sold short.

Some companies that are related to Horizon Pharma PLC include Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Theravance Biopharma (TBPH), Akcea Therapeutics (AKCA), Cambrex Corporation (CBM), Impax Laboratories (IPXL), Emergent Biosolutions (EBS), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Corium International (CORI) and Teligent (TLGT).

Horizon Pharma PLC's management team includes the folowing people:

• Timothy P. Walbert, Chairman of the Board, President, Chief Executive Officer
• Paul W. Hoelscher, Chief Financial Officer, Executive Vice President
• Barry J. Moze, Executive Vice President, Chief Administrative Officer
• Brian K. Beeler, Executive Vice President, General Counsel
• Robert F. Carey, Executive Vice President, Chief Business Officer
• Michael A. DesJardin, Executive Vice President - Technical Operations
• George P. Hampton, Executive Vice President - Primary Care Business Unit
• David A. Happel, Executive Vice President - Orphan Business Unit
• Jeffrey W. Sherman M.D., Executive Vice President - Research and Development and Chief Medical Officer
• Vikram Karnani, Senior Vice President - Rheumatology Business Unit

Horizon Pharma PLC's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.30%), Vanguard Group Inc. (7.98%), Dimensional Fund Advisors LP (3.85%), Paulson & CO. Inc. (3.02%), State Street Corp (3.00%) and Brandywine Global Investment Management LLC (2.42%). Company insiders that own Horizon Pharma PLC stock include Jeffrey W Sherman, Michael G Grey, Robert Carey and Virinder Nohria. View Institutional Ownership Trends for Horizon Pharma PLC.

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., JPMorgan Chase & Co., Hodges Capital Management Inc., Farallon Capital Management LLC, FMR LLC, Fiera Capital Corp, Cornerstone Capital Management Holdings LLC. and Voya Investment Management LLC. View Insider Buying and Selling for Horizon Pharma PLC.

Horizon Pharma PLC's stock was purchased by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Dimensional Fund Advisors LP, William Blair Investment Management LLC, Balyasny Asset Management LLC, Neuberger Berman Group LLC, State Street Corp, Brandywine Global Investment Management LLC and Ameriprise Financial Inc.. View Insider Buying and Selling for Horizon Pharma PLC.

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Horizon Pharma PLC stock can currently be purchased for approximately $12.18.